Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo

Hypertension

Volumn 44, Issue 2, 2004, Pages 195-202

  Kelly, Darren J ^a   Cox, Alison J ^a   Gow, Renae M ^a   Zhang, Yuan ^a   Kemp, Bruce E ^b   Gilbert, Richard E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Angiotensin II; Platelet derived growth factor; Transforming growth factors; Vascular diseases

Indexed keywords

ANGIOTENSIN; IMATINIB; ISOPROTEIN; LIGAND; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CONTROLLED STUDY; HEMODYNAMICS; HYPERTENSION; HYPERTROPHY; IN VIVO STUDY; MALE; MESENTERIC ARTERY; MORPHOLOGY; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; TUNICA MEDIA; VASCULAR DISEASE; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; MALE; MESENTERIC ARTERIES; MUSCLE, SMOOTH, VASCULAR; ORGAN SIZE; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS);

EID: 3543041837     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000132883.20764.12     Document Type: Article

References (45)

1. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis, Hypertension. 2001;37: 1047-1052.
2. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993;73: 413-423.
3. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
4. Hahn AW, Kern F, Buhler FR, Resink TJ. The renin-angiotensin system and extracellular matrix. Clin Investig. 1993;71:S7-12.
5. Griffin SA, Brown WC, MacPherson F, McGrath JC WVG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991;17:626-635.
6. Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res. 1997;80:607-616.
7. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431-2437.
8. Linseman DA, Benjamin CW, Jones DA. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem. 1995;270:12563-12568.
9. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, Inagami T. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998;273:8890-8896.
10. Eskildsen-Helmond YE, Mulvany MJ. Pressure-induced activation of extracellular signal-regulated kinase 1/2 in small arteries. Hypertension. 2003;41:891-897.
11. Johnson RJ, Floege J, Couser WG, Alpers CE. Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol. 1993;4:119-128.
12. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96: 1965-1991.
13. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation. 2002; 105:2296-2302.
14. Cao Z, Kelly DJ, Cox A, Casley D, Forbes JM, Martinello P, Dean R, Gilbert RE, Cooper ME. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 2000;58:2437-2451.
15. Rumble J, Komers R, Cooper M. Kinins/nitric oxide are involved in the anti-trophic effects of ACE inhibitors on diabetes associated mesenteric vascular hypertrophy. J Hypertens. 1996;14:601-607.
16. Gilbert RE, Rumble JR, Cao ZM, Cox AJ, van Eeden P, Allen TJ, Kelly DJ, Cooper ME. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res. 2000;86:158-165.
17. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 1997;45: 1559-1565.
18. Kelly DJ, Aaltonen P, Cox AJ, Rumble JR, Langham R, Panagiotopoulos S, Jerums G, Holthofer H, Gilbert RE. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant. 2002;17: 1327-1332.
19. Kim S, Zhan Y, Izumi Y, Iwao H. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. Hypertension. 2000;35:769-774.
20. Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC. Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor, key role for the adaptor protein Shc. J Biol Chem. 2000;275:15926-15932.
21. Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS. Imatinib mesylate (ST1-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res. 2002;1:89-95.
22. Chin LS, Raynor MC, Wei X, Chen HQ, Li L. Hrs interacts witfi sorting nexin 1 and regulates degradation of epidermal growth factor receptor. J Biol Chem. 2001;276:7069-7078.
23. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2:561-566.
24. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
25. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
26. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
27. Kim S, Zhan Y, Izumi Y, Yasumoto H, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol. 2000;20:2539-2545.
28. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996;379:557-560.
29. Murasawa S, Mori Y, Nozawa Y, Gotoh N, Shibuya M, Masaki H, Maruyama K, Tsutsumi Y, Moriguchi Y, Shibazaki Y, Tanaka Y, Iwasaka T, Inada M, Matsubara H. Angiotensin II type I receptor-induced extracellular signal-regulated protein kinase activation is mediated by Ca2+/calmodulin-dependent transactivation of epidermal growth factor receptor. Circ Res. 1998;82:1338-1348.
30. Moriguchi Y, Matsubara H, Mori Y, Murasawa S, Masaki H, Maruyama K, Tsutsumi Y, Shibasaki Y, Tanaka Y, Nakajima T, Oda K, Iwasaka T. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-beta synthesis via transcriptional and posttranscriptional mechanisms. Circ Res. 1999;84:1073-1084.
31. Floege J, Hudkins KL, Seifert RA, Francki A, Bowen-Pope DF, Alpers CE. Localization of PDGF alpha-receptor in the developing and mature human kidney. Kidney Int. 1997;51:1140-1150.
32. Noble NA, Border WA. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target. Seminars in Nephrology. 1997;17:455-466.
33. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol. 2000;15:264-272.
34. Laviades C, Varo N, Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension. 2000;36:517-522.
35. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis. 1999; 34:818-823.
36. Ziyadeh FN. Role of transforming growth factor beta in diabetic nephropathy. Exp Nephrol. 1994;2:137.
37. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature. 1990; 346:281-284.
38. O'Connor-McCourt MD, Wakefield LM. Latent transforming growth factor β in serum. J Biol Chem. 1987;262:14090-14099.
39. Nakao A, Roijer E, Imamura T, Souchelnytskyi S, Stenman G, Heldin CH, ten Dijke P. Identification of Smad2, a human Mad-related protein in the transforming growth factor beta signaling pathway. J Biol Chem. 1997;272:2896-2900.
40. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev. 2000;14:627-644.
41. Hedges JC, Dechert MA, Yamboliev IA, Martin JL, Hickey E, Weber LA, Gerthoffer WT. A role for p3g(MAPK)/HSP27 pathway in smooth muscle cell migration. J Biol Chem. 1999;274:24211-24219.
42. Buchdunger E, Zimmerman J, Mett H, Meyer T, Müller M, Regenass U, Lydon NB. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci. 1995;92: 2558-2562.
43. Secrist JP, Sehgal I, Powis G, Abraham RT. Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine. J Biol Chem. 1990;265:20394-20400.
44. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994;54:6106-6114.
45. Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol. 1999; 155:213-221.